Fox Business - The Power to Prosper
Search Site

AstraZeneca

Related Topics

  1. Bristol-Myers Squibb
  2. Anglo American PLC
  3. Sanofi S.A.
  4. Burberry Group PLC
  5. Royal Dutch Shell
  6. National Grid PLC
Get updates on AstraZeneca
Analysis: Drugmakers face more scrutiny of discordant U.S. prices

The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end.Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe's government-run health plans clamp down on spending and sales growth in emerging markets stutters.Now President Barack Obama's health reform law will bring more scrutiny of spending on drugs and medical care in the United States. As a result, healthcare experts say, downward pressure on drug prices will begin to mount within three to five years.That not only presents a risk to the robust profits generated by the industry, but could influence the amount of money companies chose to invest to develop innovative medicines.Drugmakers' reliance on the U.S. market "is the greatest risk to the sector," said Rajiv Kaul, portfolio manager of Fidelity Investments Select B...

Read More ›

  1. AstraZeneca 1Q Pretax Profit Down 36%

    AstraZeneca PLC (AZN.LN) Thursday reported pretax profit for first quarter of 1.3 billion dollars, down 36% from the same period last year and below analysts' expect...

  2. AstraZeneca 1Q Pretax Profit -36% From 1Q12; Backs Fiscal Year Guidance

    AstraZeneca PLC (AZN.LN) Thursday reported pretax profit for first quarter of 1.3 billion dollars, down 36% from the same period last year and below analysts' expect...

  3. EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013

    The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) first-quarter results, based on a poll of seven analysts conducted by Dow Jones Newswires...

  4. New Research Approach Tailors Drugs to Patients

    Holding the keys to the future of health care and medicine is not something many children dream of doing.But Bahija Jallal, executive vice president of AstraZeneca's...

  5. Under The Hood: An ETF For International Income

    This week has been kind to income investors looking for new ETFs to consider as Northern Trust's (NASDAQ:NTRS) FlexShares unit has rolled out three new global divide...

  6. FDA Panel Backs Approval Of Glaxo, Theravance Lung Drug

    A federal advisory panel said Wednesday a proposed lung drug from GlaxoSmithKline PLC (GSK, GSK.LN) was safe and effective at treating chronic obstructive pulmonary ...

  7. LONDON MARKETS: Miners Rebound In London; Pharma, Oil Firms Off

    U.K. stocks closed lower for a third straight day on Tuesday, with drug makers leading the charge south, while mining firms recouped some losses suffered in the prev...

  8. LONDON MARKETS: M&S Leads FTSE 100 To Fourth Day Of Gains

    Shares of Marks & Spencer Group PLC led U.K. stocks higher on Thursday after reporting fourth-quarter sales growth, while steelmaker Evraz tumbled after warning of r...

  9. Some Drug Makers Cut Payments, Meals Provided to Doctors

    Two pharmaceutical companies that are among the biggest payers of fees to doctors reduced such spending last year by double-digit percentages, as greater transparenc...

  10. AstraZeneca's new strategy gets thumbs down from S&P

    Standard & Poor's cut its credit outlook for AstraZeneca to negative from stable on Monday in response to a major strategy update by the drugmaker's new chief execut...

  11. AstraZeneca's Arthritis Pill Disappoints in Late-Stage Trial

    AstraZeneca's (NYSE:AZN) rheumatoid arthritis pill fostamatinib failed to meet one of the end goals of a late-stage clinical trial, raising doubt in the pill and the...

  12. AstraZeneca Reports Top-Line Phase III OSKIRA-1 Study of Fostamatinib

    AstraZeneca PLC (AZN.LN), a global, innovation-driven biopharmaceutical business, said Friday top-line results of OSKIRA-1--a Phase III study to assess the efficacy ...

  1. Americans Spending Less on Medicines

    Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at lea...

  2. Bristol-Myers, AstraZeneca : Study Shows Metreleptin May Treat Pediatric Lipodystrophy

    Bristol-Myers Squibb Co. (BMY) and AstraZeneca PLC (AZN) said a year-long study of metreleptin showed it reduced average blood sugar levels in pediatric patients wit...

  3. EUROPE MARKETS: Europe Stocks Rise As U.K. Avoids Recession

    European stock markets posted their longest winning streak of the year on Thursday, after U.K. economic-growth data beat expectations, showing the nation didn't slip...

  4. LONDON MARKETS: U.K. Stocks Rise As GDP Data Beat Views

    U.K. stocks climbed for a third straight day on Thursday, after better-than-expected growth data for the country, and with heavyweights British American Tobacco PLC ...

  5. EUROPE MARKETS: Europe Stocks Erase Losses After U.K. GDP

    European stock markets erased earlier losses on Thursday, after U.K. growth data beat expectations, saving the country from sliding into a triple-dip recession.The S...

  6. Mixed Results for Drug Companies

    AstraZeneca PLC (AZN.LN) said Thursday profit and sales fell for a fifth-consecutive quarter as the drug giant continues to suffer patent expiries that leave some of...

  7. LONDON MARKETS: U.K. Stocks Decline, Shrug Off GDP Data

    Weak earnings from some of the U.K.'s heavyweights weighed on London's benchmark stock index on Thursday, offsetting better-than-expected growth data for the country...

‹ Prev12345…Next ›
Freebase CC-BY
Source: AstraZeneca on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL